19
Participants
Start Date
May 1, 2011
Primary Completion Date
September 5, 2012
Study Completion Date
September 5, 2012
Romidepsin
The participants will generally continue at the same dose, infusion time and frequency used for the last dose of romidepsin given in the preceding romidepsin study. If the participant entered this rollover study in the middle of a cycle, then the cycle number and cycle day will be carried over from the preceding romidepsin study.
Florida Cancer Specialists, Sarasota
Sarah Cannon Research Institute, Nashville
Sarah Cannon Research UK, London
Lead Sponsor
Collaborators (1)
Celgene Corporation
INDUSTRY
Celgene
INDUSTRY